Business
Dyadic Presents New Business Opportunities to Address COVID-19, Influenza and Continued Scientific and Business Development Progress
JUPITER, FL / ACCESSWIRE / March 18, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on
About this update from Dyadic International, Inc.
[{"type":"text","content":"JUPITER, FL / ACCESSWIRE / March 18, 2020 / Dyadic International, Inc. (\"Dyadic\" or the \"Company\") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its management participated in the ROTH Virtual Conference on Tuesday, March 17, 2020.As a result of the precautions being taken regarding the Coronavirus outbreak, the format of the 32nd Annual ROTH Conference was changed from physical to virtual 1-on-1 meetings only. During the conference, Dyadic management presented its updated management presentation with the following highlights:Coronavirus opportunities and new research partnersNew feasibility study with University of Oslo on influenza vaccineFour novel C1 cell lines with distinct glycan patterns: Man3-9, Man3, G0 and G2A copy of the complete presentation is available on Dyadic's website by following the link below:https://www.dyadic.com/wp-content/uploads/2020/03/Investor-Presentation-March-2020.pdfAbout Dyadic International, Inc.Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Additionally, and more recently, Dyadic is also beginning to explore the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development ...